MRI for characterization of primary tumors in the non-cirrhotic liver: added value of Gd-EOB-DTPA enhanced hepatospecific phase.

PURPOSE To evaluate the added value of hepatospecific phase in Gd-EOB-DTPA enhanced magnetic resonance imaging (MRI) in patients with primary tumors in non-cirrhotic liver. METHODS Twenty-nine patients (median, 39 years; range, 18-81 years; 11 male) underwent preoperative Gd-EOB-DTPA enhanced MRI including hepatospecific phase after 10 and 20 min of contrast injection at four institutions in Europe, North America and New Zealand. Images were evaluated by three different readers (R1-R3) who characterized liver tumors with and without consultation of the hepatospecific phase images. Confidence in diagnosis was scored on a visual analog scale from 1 to 10. Histopathology (adenoma, n=5; focal nodular hyperplasia, n=11 and hepatocellular carcinoma, n=13) in all patients served as the standard of reference. Differences were evaluated using the McNemar and Wilcoxon signed rank test. RESULTS Without hepatospecific phase images available, 22 (76%), 19 (66%) and 19 (66%) of 29 tumors were characterized correctly by the three readers respectively. Mean confidence in diagnosis was 6.1, 5.7 and 5.8. With the hepatospecific phase included, characterization of liver tumors did not change significantly with 21 (72%), 23 (79%) and 19 (66%) of 29 tumors diagnosed correctly (p>0.05). According confidence ratings increased to 6.3, 6.5 and 7.7, respectively. Increase in diagnostic confidence was significant for R2 and R3 (p<0.05) and independent of reader's experience. CONCLUSION The additional hepatospecific phase in Gd-EOB-DTPA enhanced MRI did not significantly increase diagnostic accuracy in characterization of primary tumors in the non-cirrhotic liver. However, 2/3 readers showed a significant increase in diagnostic confidence after consultation of the hepatospecific phase.

[1]  H. Petrowsky,et al.  Surgical therapy of hepatocellular carcinoma , 2005, European journal of gastroenterology & hepatology.

[2]  S. Kropf,et al.  Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging , 2011, European Radiology.

[3]  E. Merkle,et al.  Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. , 2010, AJR. American journal of roentgenology.

[4]  Wolfgang Schima,et al.  Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions , 2009, European Radiology.

[5]  O. Farges,et al.  Malignant Transformation of Liver Adenoma: An Analysis of the Literature , 2010, Digestive Surgery.

[6]  A L Baert,et al.  Prolonged positive contrast enhancement with Gd‐EOB‐DTPA in experimental liver tumors: Potential value in tissue characterization , 1994, Journal of magnetic resonance imaging : JMRI.

[7]  Alexander Pfeil,et al.  Detection and classification of different liver lesions: comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation. , 2013, European journal of radiology.

[8]  M. Choti,et al.  Liver Cell Adenoma: A Multicenter Analysis of Risk Factors for Rupture and Malignancy , 2009, Annals of Surgical Oncology.

[9]  D. Sahani,et al.  Contrast-enhanced MRI of the liver with mangafodipir trisodium: imaging technique and results. , 2002, Journal of computer assisted tomography.

[10]  R. Semelka,et al.  When should abdominal magnetic resonance imaging be used? , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  G. Morana,et al.  Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. , 2005, Radiology.

[12]  T. Yamanaka,et al.  Paradoxic uptake of Gd‐EOB‐DTPA by hepatocellular carcinoma in mice: Quantitative image analysis , 1997, Journal of magnetic resonance imaging : JMRI.

[13]  I. Dagher,et al.  Management of benign hepatic tumors. , 2010, The Surgical clinics of North America.

[14]  M. Nguyen,et al.  The diagnosis and management of benign hepatic tumors. , 2005, Journal of clinical gastroenterology.

[15]  J. R. Landis,et al.  An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. , 1977, Biometrics.

[16]  Sung-whan Cho,et al.  Surgical Management of Hepatocellular Adenoma: Take It or Leave It? , 2008, Annals of Surgical Oncology.

[17]  P. Robinson,et al.  Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. , 2004, Radiology.

[18]  Rita Golfieri,et al.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis , 2011, European Radiology.

[19]  Maximilian F Reiser,et al.  Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. , 2005, Radiology.

[20]  K. Togashi,et al.  Comparison of acquired diffusion weighted imaging and computed diffusion weighted imaging for detection of hepatic metastases. , 2013, European journal of radiology.

[21]  E. Hatano,et al.  Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma , 2009, Journal of Gastroenterology.

[22]  Yong Hwan Jeon,et al.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. , 2009, AJR. American journal of roentgenology.

[23]  Nancy A Obuchowski,et al.  Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. , 2012, AJR. American journal of roentgenology.

[24]  M. Choti,et al.  Malignant transformation of hepatic adenomas , 2008, Modern Pathology.

[25]  Az Amsterdam,et al.  Diagnostic imaging of colorectal liver metastases with CT,MR imaging,FDG PET,and/or FDG PET/CT:a meta-analysis of prospective studies including patients who have not previously undergone treatment , 2011 .

[26]  Elmar M Merkle,et al.  Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. , 2010, AJR. American journal of roentgenology.

[27]  D. Weishaupt,et al.  Accuracy and confidence of Gd-EOB-DTPA enhanced MRI and diffusion-weighted imaging alone and in combination for the diagnosis of liver metastases. , 2013, European journal of radiology.

[28]  Myeong-Jin Kim,et al.  Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. , 2011, AJR. American journal of roentgenology.

[29]  Ying Lu,et al.  Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. , 2002, Radiology.

[30]  S. Schoenberg,et al.  Diagnostic Performance and Description of Morphological Features of Focal Nodular Hyperplasia in Gd-EOB-DTPA-Enhanced Liver Magnetic Resonance Imaging: Results of a Multicenter Trial , 2008, Investigative radiology.

[31]  Michael Laniado,et al.  Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions , 2008, European Radiology.